Inflammatory Signal Inhibitors for COVID-19 (MATIS)

NCT04581954 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

185

Enrollment

OTHER

Sponsor class

Conditions

Coronavirus
Covid19
Pneumonia

Interventions

DRUG: Ruxolitinib
DRUG: Fostamatinib
OTHER: Standard of care

Sponsor

Imperial College London

Collaborators

[object Object]
[object Object]
[object Object]